Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
CEL-SCI Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine In HIV/HPV Co-Infected Patients With Peri-Anal Warts 11
Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine 13
Cel-Sci Expands Co-Development Agreement with Ergomed 14
Licensing Agreements 15
CEL-SCI Enters Into Licensing Agreement With IDC-GP Pharm For Multikine 15
CEL-SCI Expands Licensing Agreement With Teva Pharma For Multikine 16
Equity Offering 17
CEL-SCI to Raise USD3.5 Million in Private Placement of Shares and Warrants 17
CEL-SCI to Raise USD2 Million in Private Placement of Shares upon Exercise of Warrants 18
CEL-SCI Raises USD1.5 Million in Private Placement of Shares and Warrants 19
CEL-SCI Raises USD1 Million in Private Placement of Shares and Warrants 21
CEL-SCI Raises USD4.3 Million in Public Offering of Shares 22
CEL-SCI Raises USD5 Million in Private Placement of Shares and Warrants 24
CEL-SCI Raises USD5 Million in Registered Direct Offering 25
Cel-Sci Raises USD11.5 Million in Public Offering of Shares and Warrants 26
Cel-Sci Raises USD16 Million in Public Offering of Shares and Warrants 28
CEL-SCI Raises USD16 Million in Public Offering of Shares and Warrants 29
Cel-Sci Raises USD6 Million in Public Offering of Shares and Warrants 30
Cel-Sci Raises USD3 Million upon Exercise of Warrants 32
Cel-Sci Completes Public Offering Of Units For US$10 Million 33
Cel-Sci Completes Public Offering Of Units For US$3.3 Million 34
Cel-Sci Completes Public Offering Of Units For US$17.8 Million 36
Cel-Sci Completes Public Offering Of Common Stock For US$11 Million 38
Cel-Sci Files Registration Statement For Public Offering Of Securities For US$50 Million 39
Cel-Sci Completes Private Placement Of Common Stock For US$6 Million 40
CEL-SCI Completes Private Placement Of Common Stock For US$5.8 Million 41
CEL-SCI Completes Registered Direct Offering Of Common Stock For US$4 Million 42
Debt Offering 44
CEL-SCI Raises USD1.2 Million in Private Placement of 4% Notes Due 2017 44
CEL-SCI Raises USD1.5 Million in Private Placement of 4% Notes Due 2017 45
CEL-SCI Corp – Key Competitors 46
CEL-SCI Corp – Key Employees 47
CEL-SCI Corp – Locations And Subsidiaries 48
Head Office 48
Recent Developments 49
Financial Announcements 49
Aug 09, 2017: CEL-SCI Reports Third Quarter Fiscal Year 2017 Financial Results 49
May 10, 2017: CEL-SCI Reports Second Quarter Fiscal Year 2017 Financial Results 50
Feb 09, 2017: CEL-SCI Reports First Quarter Fiscal 2017 Financial Results 51
Dec 14, 2016: CEL-SCI Reports Fiscal 2016 Financial Results and Clinical & Corporate Developments 52
Aug 10, 2016: CEL-SCI Reports Third Quarter Fiscal Year 2016 Financial Results 53
May 10, 2016: CEL-SCI Reports Second Quarter Fiscal Year 2016 Financial Results 54
Feb 09, 2016: CEL-SCI Reports First Quarter Fiscal 2016 Financial Results 55
Corporate Communications 56
Feb 27, 2017: CEL-SCI Announces That the NYSE MKT Approves Plan 56
Dec 09, 2016: CEL-SCI Reports on NYSE MKT Noncompliance Notice and Compliance Plan 57
Sep 06, 2016: CEL-SCI Announces Resignation of its Founder for Health Reasons 58
Government and Public Interest 59
Sep 19, 2017: CEL-SCI Announces $1.5 Million NIH SBIR Grant to Support Development of Rheumatoid Arthritis Vaccine 59
Product News 60
05/16/2017: CEL-SCI Scientist Presents Data on CEL-4000 at AAI – IMMUNOLOGY 2017 Meeting 60
04/12/2017: CEL-SCI Scientist Presents at the World Vaccine Congress 61
02/23/2016: CEO Geert Kersten Summarizes CEL-SCI Phase 3 Cancer Immunotherapy Progress in a New Video Interview 62
02/21/2017: CEL-SCI Scientist Presents New Findings for Rheumatoid Arthritis Treatment Vaccine at Conference 63
Clinical Trials 64
Jun 08, 2017: CEL-SCI Announces New Data for Its Rheumatoid Arthritis Vaccine Candidate Published in Peer Reviewed Journal 64
Nov 14, 2016: CEL-SCI Reports Preclinical Data Showing LEAPS Vaccine is Successful in Treating Rheumatoid Arthritis 65
Oct 21, 2016: CEL-SCI Provides Update on Partial Clinical Hold on Phase 3 Clinical Trial 66
Sep 26, 2016: CEL-SCI Reports Clinical Hold on Head and Neck Cancer Study 67
Sep 02, 2016: CEL-SCI Reports Monthly Patient Enrollment in August for Its Phase 3 Head and Neck Cancer Trial 68
Aug 01, 2016: CEL-SCI Reports Monthly Patient Enrollment in July for Its Phase 3 Head and Neck Cancer Trial 69
Jul 05, 2016: CEL-SCI Reports Monthly Patient Enrollment in June for Its Phase 3 Head and Neck Cancer Trial 70
Jun 01, 2016: CEL-SCI Reports Monthly Patient Enrollment in May for Its Phase 3 Head and Neck Cancer Trial 71
May 02, 2016: CEL-SCI Reports Record Monthly Patient Enrollment in April for Its Phase 3 Head and Neck Cancer Trial 72
Apr 01, 2016: CEL-SCI Reports Monthly Patient Enrollment in March for Its Phase 3 Head and Neck Cancer Trial 73
Mar 01, 2016: CEL-SCI Reports Monthly Patient Enrollment in February for Its Phase 3 Head and Neck Cancer Trial 74
Feb 01, 2016: CEL-SCI Reports Monthly Patient Enrollment in January for Its Phase 3 Head and Neck Cancer Trial 75
Jan 08, 2016: Cel-Sci Summarizes Significant Accomplishments In 2015 And Positive Momentum For 2016 76
Jan 05, 2016: CEL-SCI Reports Record Year for Patient Enrollment with 75% Increase in Its Global Phase 3 Head and Neck Cancer Trial 78
Appendix 79
Methodology 79
About GlobalData 79
Contact Us 79
Disclaimer 79
CEL-SCI Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
CEL-SCI Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
CEL-SCI Corp, Deals By Therapy Area, 2011 to YTD 2017 9
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine In HIV/HPV Co-Infected Patients With Peri-Anal Warts 11
Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine 13
Cel-Sci Expands Co-Development Agreement with Ergomed 14
CEL-SCI Enters Into Licensing Agreement With IDC-GP Pharm For Multikine 15
CEL-SCI Expands Licensing Agreement With Teva Pharma For Multikine 16
CEL-SCI to Raise USD3.5 Million in Private Placement of Shares and Warrants 17
CEL-SCI to Raise USD2 Million in Private Placement of Shares upon Exercise of Warrants 18
CEL-SCI Raises USD1.5 Million in Private Placement of Shares and Warrants 19
CEL-SCI Raises USD1 Million in Private Placement of Shares and Warrants 21
CEL-SCI Raises USD4.3 Million in Public Offering of Shares 22
CEL-SCI Raises USD5 Million in Private Placement of Shares and Warrants 24
CEL-SCI Raises USD5 Million in Registered Direct Offering 25
Cel-Sci Raises USD11.5 Million in Public Offering of Shares and Warrants 26
Cel-Sci Raises USD16 Million in Public Offering of Shares and Warrants 28
CEL-SCI Raises USD16 Million in Public Offering of Shares and Warrants 29
Cel-Sci Raises USD6 Million in Public Offering of Shares and Warrants 30
Cel-Sci Raises USD3 Million upon Exercise of Warrants 32
Cel-Sci Completes Public Offering Of Units For US$10 Million 33
Cel-Sci Completes Public Offering Of Units For US$3.3 Million 34
Cel-Sci Completes Public Offering Of Units For US$17.8 Million 36
Cel-Sci Completes Public Offering Of Common Stock For US$11 Million 38
Cel-Sci Files Registration Statement For Public Offering Of Securities For US$50 Million 39
Cel-Sci Completes Private Placement Of Common Stock For US$6 Million 40
CEL-SCI Completes Private Placement Of Common Stock For US$5.8 Million 41
CEL-SCI Completes Registered Direct Offering Of Common Stock For US$4 Million 42
CEL-SCI Raises USD1.2 Million in Private Placement of 4% Notes Due 2017 44
CEL-SCI Raises USD1.5 Million in Private Placement of 4% Notes Due 2017 45
CEL-SCI Corp, Key Competitors 46
CEL-SCI Corp, Key Employees 47